{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:03:37Z","timestamp":1789884217787,"version":"4.0.1"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.critrevonc.2026.105611","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:41:21Z","timestamp":1789882881000},"page":"105611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Beyond the Generic Tumor: Engineering Patient-Specific Immune Ecosystems for Cancer"],"prefix":"10.1016","author":[{"given":"Samira","family":"Anvari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal","family":"Naghinezhad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8812-3845","authenticated-orcid":false,"given":"Reza","family":"Farokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid Akhavan","family":"Rahnama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saghar","family":"Hoseinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-5424","authenticated-orcid":false,"given":"Mohsen","family":"Nikbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmadvand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105611_bib1","doi-asserted-by":"crossref","unstructured":"Anderson L., Mason N.J., O\u2019Connor R.S. Engineering T cell metabolism to enhance therapeutic efficacy. In: 2026:117-139. doi:10.1016\/bs.apha.2026.05.001","DOI":"10.1016\/bs.apha.2026.05.001"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s11033-026-11990-w","article-title":"Harnessing CAR-NK cells against multiple myeloma: current landscape and future directions","volume":"53","author":"Anvari","year":"2026","journal-title":"Mol Biol Rep"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105611_bib3","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/s43018-025-00979-2","article-title":"Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer","volume":"6","author":"Apavaloaei","year":"2025","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA\u2014a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integr Peer Rev"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib5","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1186\/s12967-026-08535-x","article-title":"AI-driven neoantigen identification: a comprehensive review from somatic variant calling to T cell recognition","volume":"24","author":"Bakhshian","year":"2026","journal-title":"J Transl Med"},{"key":"10.1016\/j.critrevonc.2026.105611_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.01215","article-title":"Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal","volume":"11","author":"Bianchi","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib7","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","article-title":"Advances in the development of personalized neoantigen-based therapeutic cancer vaccines","volume":"18","author":"Blass","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105611_bib8","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41590-023-01543-9","article-title":"Neoantigen-specific stem cell memory-like CD4+ T cells mediate CD8+ T cell-dependent immunotherapy of MHC class II-negative solid tumors","volume":"24","author":"Brightman","year":"2023","journal-title":"Nat Immunol"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105611_bib9","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105611_bib10","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/mt.2015.90","article-title":"mRNA-transfected Dendritic Cells Expressing Polypeptides That Link MHC-I Presentation to Constitutive TLR4 Activation Confer Tumor Immunity","volume":"23","author":"Cafri","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.critrevonc.2026.105611_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1678896","article-title":"Toll-like receptor activation and gene delivery efficiency in canine dendritic cells: a model for comparative oncology","volume":"16","author":"Capellero","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105611_bib12","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.2017","article-title":"Better, Faster, Stronger: Accelerating <scp>mRNA<\/scp> \u2010Based Immunotherapies With Nanocarriers","volume":"16","author":"Carvalho","year":"2024","journal-title":"WIREs Nanomedicine and Nanobiotechnology"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105611_bib13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/s41571-024-00926-7","article-title":"Spatial landscapes of cancers: insights and opportunities","volume":"21","author":"Chen","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib14","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1186\/s12967-025-07259-8","article-title":"Innovative gene engineering strategies to address tumor antigen escape in cell therapy","volume":"23","author":"Chen","year":"2025","journal-title":"J Transl Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib15","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12929-024-01082-x","article-title":"Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens","volume":"31","author":"Chi","year":"2024","journal-title":"J Biomed Sci"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105611_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41587-021-01038-8","article-title":"Identification of tumor antigens with immunopeptidomics","volume":"40","author":"Chong","year":"2022","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41392-020-00448-5","article-title":"Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer","volume":"6","author":"Ding","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib18","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13073-025-01569-8","article-title":"PredIG: an interpretable predictor of T-cell epitope immunogenicity","volume":"17","author":"Farriol-Duran","year":"2025","journal-title":"Genome Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib19","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/mas.21905","article-title":"Exploring the dynamic landscape of immunopeptidomics: Unravelling posttranslational modifications and navigating bioinformatics terrain","volume":"44","author":"Flender","year":"2025","journal-title":"Mass Spectrom Rev"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib20","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.ymthe.2019.01.018","article-title":"The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy","volume":"27","author":"Foster","year":"2019","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105611_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2026.189577","article-title":"mRNA-based cancer vaccines: A new frontier in personalized immunotherapy","volume":"1881","author":"Garg","year":"2026","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105611_bib22","doi-asserted-by":"crossref","first-page":"465","DOI":"10.2174\/0109298665373152250625054723","article-title":"Innovative Immunoinformatics Tools for Enhancing MHC (Major Histocompatibility Complex) Class I Epitope Prediction in Immunoproteomics","volume":"32","author":"Gomase","year":"2025","journal-title":"Protein Pept Lett"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105611_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.108557","article-title":"Harnessing bacteria for tumor therapy: Current advances and challenges","volume":"35","author":"Guo","year":"2024","journal-title":"Chinese Chem Lett"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105611_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2025.102399","article-title":"situ extended immune activation instantly after tumor resection by oncolytic virus controls postoperative tumor recurrence","volume":"6","author":"Guo","year":"2025","journal-title":"Cell Reports Med"},{"key":"10.1016\/j.critrevonc.2026.105611_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1535826","article-title":"Regulatory T cell epitope content in human antibodies decreases during maturation","volume":"16","author":"Gutierrez","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40164-026-00744-w","article-title":"Hijacking the helpers: platelet and neutrophil trafficking in AML and therapeutic exploitation","volume":"15","author":"Heydari","year":"2026","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib27","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-026-00957-5","article-title":"Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence","author":"Heydari","year":"2026","journal-title":"Biomark Res"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105611_bib28","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41577-025-01208-8","article-title":"Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development","volume":"26","author":"Huber","year":"2026","journal-title":"Nat Rev Immunol"},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105611_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.174027","article-title":"CD4 T cell\u2013activating neoantigens enhance personalized cancer vaccine efficacy","volume":"8","author":"Huff","year":"2023","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13073-016-0264-5","article-title":"pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens","volume":"8","author":"Hundal","year":"2016","journal-title":"Genome Med"},{"issue":"19","key":"10.1016\/j.critrevonc.2026.105611_bib32","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti\u2013PD-1\u2013Based Immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105611_bib33","doi-asserted-by":"crossref","unstructured":"H\u00f8nn\u00e5shagen T.K., Skoge L.J., S\u00e6b\u00f8e-Larssen S., H\u00e5kenstad H., Kvalheim G., Sioud M. Production of mRNA-Loaded Dendritic Cell Cancer Vaccines. In: 2025:245-258. doi:10.1007\/978-1-0716-4742-4_11","DOI":"10.1007\/978-1-0716-4742-4_11"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105611_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101516","article-title":"Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum","volume":"5","author":"Ingels","year":"2024","journal-title":"Cell Reports Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105611_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/pcmedi\/pbae017","article-title":"Lipid nanoparticle-based mRNA vaccines: a new frontier in precision oncology","volume":"7","author":"Jacob","year":"2024","journal-title":"Precis Clin Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105611_bib36","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/s41568-021-00339-z","article-title":"Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion","volume":"21","author":"Jhunjhunwala","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.critrevonc.2026.105611_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217427","article-title":"Driver mutation landscape of acute myeloid leukemia provides insights for neoantigen-based immunotherapy","volume":"611","author":"Jin","year":"2025","journal-title":"Cancer Lett"},{"key":"10.1016\/j.critrevonc.2026.105611_bib38","article-title":"Adjuvant Therapy With PD1\/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis","volume":"12","author":"Jin","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib39","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1869389","article-title":"Advances in identification and selection of personalized neoantigen\/T-cell pairs for autologous adoptive T cell therapies","volume":"10","author":"Kast","year":"2021","journal-title":"Oncoimmunology"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105611_bib40","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.18632\/oncotarget.24232","article-title":"Effective screening of T cells recognizing neoantigens and construction of T-cell receptor-engineered T cells","volume":"9","author":"Kato","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.critrevonc.2026.105611_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489827","article-title":"Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors","volume":"15","author":"Khan","year":"2025","journal-title":"Front Immunol"},{"issue":"8_ement","key":"10.1016\/j.critrevonc.2026.105611_bib42","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2023-CT001","article-title":"Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201\/Keynote-942 trial","volume":"83","author":"Khattak","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2026.105611_bib43","doi-asserted-by":"crossref","DOI":"10.1200\/JCO-26-00835","article-title":"Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study","author":"Khattak","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.785231","article-title":"A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKK\u03b2-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma","volume":"13","author":"Koch","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105611_bib45","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/biochem5020005","article-title":"Advances in Personalized Cancer Vaccine Development: AI Applications from Neoantigen Discovery to mRNA Formulation","volume":"5","author":"Kong","year":"2025","journal-title":"BioChem"},{"key":"10.1016\/j.critrevonc.2026.105611_bib46","doi-asserted-by":"crossref","unstructured":"Kumar A., Dwivedi D., Gopalakrishnan K., et al. iPSC-Derived Polyvalent Vaccines as Ontogenetically Informed Immunogens for Overcoming Immune Refractoriness in Microsatellite-Stable Colorectal Cancer: A New Frontier in Cancer Immunotherapy. Preprint posted online November 25, 2025. doi:10.20944\/preprints202511.1853.v1","DOI":"10.20944\/preprints202511.1853.v1"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib47","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105611_bib48","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008645","article-title":"Neoantigen-specific stimulation of tumor-infiltrating lymphocytes enables effective TCR isolation and expansion while preserving stem-like memory phenotypes","volume":"12","author":"Levin","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12943-025-02426-3","article-title":"Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment","volume":"24","author":"Le","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.critrevonc.2026.105611_bib50","article-title":"Unveiling the immunological landscape: comprehensive characterization of neoantigen-reactive immune cells in neoantigen cancer vaccines","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib51","first-page":"1","article-title":"Current progress in neoantigen-based dendritic cell vaccines for solid tumors","author":"Li","year":"2025","journal-title":"Cancer Biol Med"},{"issue":"48","key":"10.1016\/j.critrevonc.2026.105611_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202514661","article-title":"Spatial Transcriptomics and snRNA\u2010seq Expose CAF Niches Orchestrating Dual Stromal\u2010Immune Barriers in Hepatocellular Carcinoma","volume":"12","author":"Li","year":"2025","journal-title":"Adv Sci"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105611_bib53","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13402-026-01199-1","article-title":"Next-generation neoantigen mRNA vaccines: Immuno-engineering strategies for precision cancer immunotherapy","volume":"49","author":"Li","year":"2026","journal-title":"Cell Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41392-023-01644-9","article-title":"Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope","volume":"8","author":"Li","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12943-023-01844-5","article-title":"The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells","volume":"22","author":"Li","year":"2023","journal-title":"Mol Cancer"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105611_bib56","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003001","article-title":"Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies","volume":"9","author":"Lo","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib57","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/HEP.0000000000000600","article-title":"Spatial proximity of tumor-immune interactions predicts patient outcome in hepatocellular carcinoma","volume":"79","author":"Maestri","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105611_bib58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40203-025-00459-6","article-title":"Artificial intelligence, structural, and immunoinformatics-driven multi-epitope vaccine design targeting non-structural proteins of West Nile Virus","volume":"13","author":"Mallick","year":"2025","journal-title":"Silico Pharmacol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib59","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-cancerbio-061521-082114","article-title":"Targeting Driver Oncogenes and Other Public Neoantigens Using T Cell Receptor\u2013Based Cellular Therapy","volume":"7","author":"Martinov","year":"2023","journal-title":"Annu Rev Cancer Biol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib60","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.omtn.2022.08.021","article-title":"A synthetic DNA template for fast manufacturing of versatile single epitope mRNA","volume":"29","author":"de Mey","year":"2022","journal-title":"Mol Ther - Nucleic Acids"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105611_bib61","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1158\/1078-0432.CCR-21-3304","article-title":"RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System","volume":"28","author":"De Mey","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"736","key":"10.1016\/j.critrevonc.2026.105611_bib62","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj9905","article-title":"A functional identification platform reveals frequent, spontaneous neoantigen-specific T cell responses in patients with cancer","volume":"16","author":"Miller","year":"2024","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.critrevonc.2026.105611_bib63","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2026.10043","article-title":"The Tumor\u2013Platelet\u2013Immune Interface: Driving Metastasis, Pre-Metastatic Niche Formation and Therapeutic Vulnerabilities","volume":"28","author":"Naghinezhad","year":"2026","journal-title":"Expert Rev Mol Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105611_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2023.100978","article-title":"mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy","volume":"4","author":"Olivera","year":"2023","journal-title":"Cell Reports Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105611_bib65","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41587-026-03018-2","article-title":"The promises and challenges of neoantigen cancer vaccines","volume":"44","author":"Ott","year":"2026","journal-title":"Nat Biotechnol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges","volume":"11","author":"Pang","year":"2023","journal-title":"Biomark Res"},{"key":"10.1016\/j.critrevonc.2026.105611_bib67","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.2147\/IJN.S541061","article-title":"Advancing Cancer Immunotherapy Using Lipid Nanoparticle-Based Approaches","volume":"20","author":"Prazeres","year":"2025","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.critrevonc.2026.105611_bib68","doi-asserted-by":"crossref","unstructured":"Pr\u00e9lot L., Chen J., H\u00fcser M., Kahles A., R\u00e4tsch G. ImmunoPepper: Extracting personalized peptides from complex splicing graphs. Kendziorski C, ed. Bioinformatics. Published online October 9, 2025. doi:10.1093\/bioinformatics\/btaf492","DOI":"10.1093\/bioinformatics\/btaf492"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13073-019-0666-2","article-title":"Best practices for bioinformatic characterization of neoantigens for clinical utility","volume":"11","author":"Richters","year":"2019","journal-title":"Genome Med"},{"key":"10.1016\/j.critrevonc.2026.105611_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295208","article-title":"NLRC5 overexpression in ovarian tumors remodels the tumor microenvironment and increases T-cell reactivity toward autologous tumor-associated antigens","volume":"14","author":"Rodriguez","year":"2024","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105611_bib71","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010249","article-title":"Neoantigen architectures define immunogenicity and drive immune evasion of tumors with heterogenous neoantigen expression","volume":"12","author":"Roerden","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"7963","key":"10.1016\/j.critrevonc.2026.105611_bib72","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105611_bib73","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/s41551-019-0436-x","article-title":"Engineering patient-specific cancer immunotherapies","volume":"3","author":"Scheetz","year":"2019","journal-title":"Nat Biomed Eng"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib74","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1146\/annurev-immunol-042617-053402","article-title":"Cancer Neoantigens","volume":"37","author":"Schumacher","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"8056","key":"10.1016\/j.critrevonc.2026.105611_bib75","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105611_bib76","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.trecan.2026.02.003","article-title":"From prediction to precision: how immunopeptidomics advances neoantigen discovery","volume":"12","author":"Shapiro","year":"2026","journal-title":"Trends in Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105611_bib77","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ymthe.2020.09.038","article-title":"Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities","volume":"29","author":"Shemesh","year":"2021","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105611_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2023.100670","article-title":"Systems immunology spanning tumors, lymph nodes, and periphery","volume":"3","author":"Sidiropoulos","year":"2023","journal-title":"Cell Reports Methods"},{"key":"10.1016\/j.critrevonc.2026.105611_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113392","article-title":"Unlocking the full potential of memory T cells in adoptive T cell therapy for hematologic malignancies","volume":"144","author":"Sun","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib80","article-title":"Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer","volume":"14","author":"Tang","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib81","doi-asserted-by":"crossref","unstructured":"Tatsuno K., Vassall A., Hanlon D., et al. An anti-cancer cell therapy platform utilizing ex vivo physiologic dendritic cells expressing mRNA-encoded antigens and immune checkpoint blockers. Preprint posted online May 30, 2025. doi:10.21203\/rs.3.rs-6480245\/v1","DOI":"10.21203\/rs.3.rs-6480245\/v1"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib82","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41541-025-01258-y","article-title":"AI-driven epitope prediction: a systematic review, comparative analysis, and practical guide for vaccine development","volume":"10","author":"Villanueva-Flores","year":"2025","journal-title":"npj Vaccines"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105611_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/prca.70018","article-title":"Artificial Intelligence and the Evolving Landscape of Immunopeptidomics","volume":"19","author":"Vo","year":"2025","journal-title":"PROTEOMICS \u2013 Clin Appl"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105611_bib84","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib85","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s40364-025-00808-9","article-title":"Computation strategies and clinical applications in neoantigen discovery towards precision cancer immunotherapy","volume":"13","author":"Wang","year":"2025","journal-title":"Biomark Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105611_bib86","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/cpt.70020","article-title":"Clinical Pharmacology Characterization of Bispecific T\u2010Cell Engagers: A Summary Based on FDA Approvals","volume":"119","author":"Wang","year":"2026","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105611_bib87","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41568-024-00723-5","article-title":"Enhancing cellular immunotherapies in cancer by engineering selective therapeutic resistance","volume":"24","author":"Wellhausen","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105611_bib88","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.critrevonc.2026.105611_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113664","article-title":"Transdermal psoriasis treatment inspired by tumor microenvironment-mediated immunomodulation and advanced by exosomal engineering","volume":"382","author":"Yang","year":"2025","journal-title":"J Control Release"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib90","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/s41591-024-02894-y","article-title":"Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1\/2 trial","volume":"30","author":"Yarchoan","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105611_bib91","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/JP9.0000000000000237","article-title":"Neoantigens in the application of adoptive cell therapy for solid tumors","volume":"8","author":"Yuan","year":"2025","journal-title":"J Pancreatol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib92","article-title":"Neoantigen-based cancer vaccines: a mechanistic and clinical review of personalised melanoma immunotherapy","volume":"17","author":"Yu","year":"2026","journal-title":"Front Immunol"},{"key":"10.1016\/j.critrevonc.2026.105611_bib93","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1684655","article-title":"mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors","volume":"16","author":"Zagorac","year":"2025","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105611_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007073","article-title":"Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery","volume":"11","author":"Zhang","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.critrevonc.2026.105611_bib95","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105611_bib96","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/s41435-024-00305-3","article-title":"Neoantigen-specific mRNA\/DC vaccines for effective anticancer immunotherapy","volume":"25","author":"Zhang","year":"2024","journal-title":"Genes Immun"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib97","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf302","article-title":"Computational methods and data resources for predicting tumor neoantigens","volume":"26","author":"Zhao","year":"2025","journal-title":"Brief Bioinform"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105611_bib98","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ccell.2022.03.005","article-title":"Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers","volume":"40","author":"Zheng","year":"2022","journal-title":"Cancer Cell"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:41:37Z","timestamp":1789882897000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":98,"alternative-id":["S1040842826004981"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105611","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the Generic Tumor: Engineering Patient-Specific Immune Ecosystems for Cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105611","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105611"}}